Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 9/20 | 0.34 |
| ▸ | FGFR3 | P22607 | 8/20 | 0.34 |
| ▸ | ACVRL1 | P37023 | 6/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.34 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.32 |
| ▸ | AXL | P30530 | 1/20 | 0.32 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.32 |
| ▸ | MERTK | Q12866 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23337825 | 0.86 | FGFR1 (0.37) | FGFR1FGFR3ACVRL1PIK3CDTNK2 | |
| SCHEMBL23861738 | 0.79 | AURKB (0.36) | FGFR1PIK3CD | |
| SCHEMBL25715807 | 0.78 | ACVRL1 (0.34) | FGFR1FGFR3ACVRL1PIK3CDTNK2 | |
| SCHEMBL22696564 | 0.75 | RIPK1 (0.37) | FGFR1FGFR3TNK2 | |
| SCHEMBL25557835 | 0.75 | FGFR1 (0.33) | FGFR1ACVRL1PIK3CD | |
| SCHEMBL25715809 | 0.74 | PIK3CD (0.36) | FGFR1FGFR3ACVRL1PIK3CDTNK2 | |
| SCHEMBL25557493 | 0.73 | RIPK1 (0.37) | FGFR1FGFR3TNK2 | |
| SCHEMBL23337817 | 0.72 | BTK (0.44) | FGFR1FGFR3ACVRL1 | |
| SCHEMBL23337815 | 0.72 | BTK (0.44) | FGFR1FGFR3ACVRL1 | |
| SCHEMBL23861722 | 0.72 | BTK (0.44) | FGFR1FGFR3ACVRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11130761-B2 | Substituted pyrrolo[2,1-f][1,2,4]triazines as FGFR inhibitors | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2021-09-28 | — | — | US | disclosed |
| US-20210130357-A1 | FGFR INHIBITOR | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2021-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11130761-B2 | Substituted pyrrolo[2,1-f][1,2,4]triazines as FGFR inhibitors | FGFR1, FGFR2, FGFR4 | FGFR1 1/4885FGFR3 4/4885ACVRL1 156/4885 |
| US-20210130357-A1 | FGFR INHIBITOR | FGFR1, FGFR2, FGFR3 | FGFR1 1/4885FGFR3 3/4885ACVRL1 144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.